Related references
Note: Only part of the references are listed.Genome-wide association study identifies HLA-A*3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population
Takeshi Ozeki et al.
HUMAN MOLECULAR GENETICS (2011)
HLA-A*3101 and Carbamazepine-Induced Hypersensitivity Reactions in Europeans
Mark McCormack et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Association between HLA-B*1502 and carbamazepine-induced severe cutaneous adverse drug reactions in a Thai population
Wichittra Tassaneeyakul et al.
EPILEPSIA (2010)
Clinically Available Pharmacogenomics Tests
D. A. Flockhart et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2009)
Association of HLA-B*1502 allele and carbamazepine-induced Stevens-Johnson syndrome among Indians
Timir Y. Mehta et al.
INDIAN JOURNAL OF DERMATOLOGY VENEREOLOGY & LEPROLOGY (2009)
Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLA-B*1502 allele in Thai population
Chaichon Locharernkul et al.
EPILEPSIA (2008)
Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis
Wen-Hung Chung et al.
NATURE MEDICINE (2008)
HLA-B*1502-bound peptides: Implications for the pathogenesis of carbamazepine-induced Stevens-Johnson syndrome
Chih-Wen Ou Yang et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2007)
Association between HLA-B*1502 allele and antiepileptic drug-induced cutaneous reactions in han Chinese
Celeste B. L. Man et al.
EPILEPSIA (2007)
Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions
Shuen-Lu Hung et al.
PHARMACOGENETICS AND GENOMICS (2006)
Toxic epidermal necrolysis and Stevens-Johnson syndrome - Does early withdrawal of causative drugs decrease the risk of death?
I Garcia-Doval et al.
ARCHIVES OF DERMATOLOGY (2000)
Share Paper
